NGNE

Neurogene Inc. NASDAQ Listed Mar 7, 2014

Healthcare ·Biotechnology ·US · neurogene.com

$32.33

After hrs $32.04 -0.90%

Mkt Cap $504.9M

52w Low $12.97 79.7% of range 52w High $37.27

50d MA $22.83 200d MA $21.88

P/E (TTM) -6.3x

EV/EBITDA -3.3x

P/B 2.1x

Debt/Equity 0.0x

ROE -34.1%

P/FCF -5.6x

RSI (14) —

ATR (14) —

Beta 1.89

50d MA $22.83

200d MA $21.88

Avg Volume 174.3K

About

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 24, 2026	AMC	-1.24	-1.12	+9.6%	20.90	+1.6%	+5.4%	+2.4%	-2.6%	-7.7%	-3.5%	—
Nov 13, 2025	AMC	-1.26	-0.99	+21.4%	26.49	+1.7%	-14.0%	-15.2%	-19.4%	-20.8%	-23.0%	—
Aug 11, 2025	AMC	-1.15	-1.05	+8.7%	20.35	-1.9%	-5.6%	+3.7%	-0.7%	+0.8%	+0.5%	—
May 9, 2025	AMC	-1.05	-1.08	-2.9%	14.73	+5.1%	+20.2%	+5.3%	+3.3%	+31.5%	+22.1%	—
Mar 24, 2025	AMC	-1.04	-0.99	+4.8%	13.96	+1.5%	+1.7%	+15.6%	+9.8%	+4.0%	-16.1%	—
Nov 18, 2024	AMC	-1.22	-1.19	+2.5%	19.82	+5.4%	-13.1%	-22.7%	-21.3%	+2.4%	+12.6%	—
Aug 9, 2024	AMC	-1.02	-1.09	-6.9%	35.59	-1.3%	-2.5%	-4.0%	-5.7%	+0.1%	-1.6%	—
May 10, 2024	AMC	-1.03	-1.00	+2.9%	32.50	-1.3%	-5.7%	-2.9%	+3.4%	+3.8%	+2.5%	—
Mar 26, 2024	AMC	-1.17	-1.51	-29.1%	49.45	-0.1%	-0.4%	+2.9%	-5.4%	-9.8%	-11.1%	—
Nov 14, 2023	AMC	-0.80	-0.41	+48.8%	14.00	-2.3%	-1.4%	-6.0%	-4.3%	-5.7%	-7.4%	—
Aug 10, 2023	AMC	-0.15	-0.04	+73.3%	12.64	-0.3%	-1.9%	-2.1%	+6.0%	+10.6%	+14.6%	—
Mar 30, 2023	AMC	-4.40	-0.26	+94.2%	13.90	-0.7%	+0.7%	+0.7%	-2.2%	+3.6%	+0.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 6	Canaccord Genuity	Maintains	Buy → Buy	—	$20.69	$20.69	+0.0%	-1.1%	+1.1%	+4.4%	+3.3%	-1.5%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.28	$17.26	-0.1%	-1.9%	+8.8%	+4.5%	+1.6%	+1.4%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$31.08	$30.24	-2.7%	-14.8%	-26.7%	-27.7%	-31.3%	-32.5%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.14	$34.46	+4.0%	+3.4%	-6.3%	-4.0%	-16.4%	-19.6%
Oct 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.83	$26.62	+3.1%	+22.2%	+17.0%	+22.4%	+28.5%	+33.1%
Jun 12	BMO Capital	Maintains	Outperform → Outperform	—	$20.92	$21.43	+2.4%	-2.5%	-5.5%	-9.3%	-12.0%	-12.5%
May 20	BMO Capital	Maintains	Outperform → Outperform	—	$19.52	$20.39	+4.5%	-5.0%	-10.4%	-7.6%	-11.5%	-12.4%
May 16	Baird	Downgrade	Outperform → Neutral	—	$19.37	$18.20	-6.0%	-7.1%	+0.8%	-4.2%	-9.7%	-6.9%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.70	$17.21	-2.8%	-12.4%	-14.0%	+9.4%	+1.6%	+10.3%
Apr 14	BMO Capital	Maintains	Outperform → Outperform	—	$11.00	$10.97	-0.3%	-1.0%	+3.3%	-2.1%	+4.5%	+9.3%
Mar 25	Baird	Maintains	Outperform → Outperform	—	$13.96	$14.17	+1.5%	+1.7%	+15.6%	+9.8%	+4.0%	-16.1%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.96	$14.17	+1.5%	+1.7%	+15.6%	+9.8%	+4.0%	-16.1%
Nov 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.30	$21.05	+3.7%	+10.0%	+32.4%	+27.1%	+25.3%	+21.0%
Nov 20	BMO Capital	Maintains	Outperform → Outperform	—	$17.23	$17.31	+0.5%	-11.0%	-9.5%	+17.8%	+29.5%	+55.9%
Nov 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.82	$20.90	+5.4%	-13.1%	-22.7%	-21.3%	+2.4%	+12.6%
Nov 12	Leerink Partners	Maintains	Outperform → Outperform	—	$71.53	$48.28	-32.5%	-44.1%	-44.6%	-45.2%	-51.7%	-72.3%
Nov 12	Baird	Maintains	Outperform → Outperform	—	$71.53	$48.28	-32.5%	-44.1%	-44.6%	-45.2%	-51.7%	-72.3%
Nov 12	Stifel	Maintains	Buy → Buy	—	$71.53	$48.28	-32.5%	-44.1%	-44.6%	-45.2%	-51.7%	-72.3%
Nov 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$71.53	$48.28	-32.5%	-44.1%	-44.6%	-45.2%	-51.7%	-72.3%
Nov 12	BMO Capital	Maintains	Outperform → Outperform	—	$71.53	$48.28	-32.5%	-44.1%	-44.6%	-45.2%	-51.7%	-72.3%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.59	$35.12	-1.3%	-2.5%	-4.0%	-5.7%	+0.1%	-1.6%
Jun 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$30.32	$30.50	+0.6%	+2.5%	+2.3%	+4.7%	+2.6%	+5.6%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.23	$37.75	+1.4%	+1.3%	+0.6%	-0.2%	+1.7%	+0.3%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.50	$32.09	-1.3%	-5.7%	-2.9%	+3.4%	+3.8%	+2.5%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.94	$32.80	-3.4%	-3.1%	-2.2%	-4.2%	-9.7%	-7.0%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.39	$36.02	+1.8%	+3.5%	-7.3%	-4.1%	-7.0%	-6.2%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.55	$39.90	+6.3%	+20.0%	+19.3%	+31.1%	+32.8%	+30.6%
Mar 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.55	$38.55	+0.0%	-3.4%	-1.5%	+0.3%	-3.4%	-5.4%
Jan 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.30	$33.25	+2.9%	-6.6%	-6.5%	-6.8%	-6.8%	-6.1%

Recent Filings

8-K · 7.01 ! Medium

Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure

Neurogene disclosed material information via press release but the 8-K summary doesn't specify the content, so investors should review Exhibit 99.1 directly to assess relevance to NGNE stock.

Apr 20

8-K

Unknown — 8-K Filing

Completion of Embolden trial enrollment and Breakthrough Therapy designation for NGN-401 significantly accelerate NGNE's path to FDA approval, potentially enabling faster commercialization and reducing development risk for this clinical-stage biotech.

Mar 24

8-K · 7.01 ! Medium

Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure

Neurogene disclosed material information via press release without specifying details, requiring investors to review the attached exhibit to assess potential impacts on the gene therapy company's operations or financial outlook.

Feb 26

Data updated apr 26, 2026 2:57pm · Source: massive.com